Table 3 Univariate and multivariate analyses for overall survival
Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
Crude HR (95%CI) | p value | Adjusted HR (95%CI) | p value | |
Age ≥ 65 years | 1.71 (1.24, 2.36) | 0.001 | 1.6 (1.12, 2.3) | 0.01 |
Male | 0.78 (0.61, 1) | 0.052 | 0.73 (0.54, 1) | 0.052 |
Smoking | 1.66 (1.32, 2.09) | < 0.001 | 1.01 (0.75, 1.36) | 0.938 |
Stage at diagnosis | ||||
I/II | Reference | 1 | Reference | 1 |
III | 1.45 (0.99, 2.14) | 0.057 | 1.48 (0.98, 2.22) | 0.061 |
IVab | 3.4 (2.33, 4.95) | < 0.001 | 3.35 (2.26, 4.96) | < 0.001 |
BMI | ||||
18.5–22.9 | Reference | 1 | Reference | 1 |
< 18.5 | 1.71 (1.18, 2.48) | 0.005 | 1.49 (1, 2.22) | 0.051 |
≥ 23 | 0.65 (0.51, 0.82) | < 0.001 | 0.68 (0.53, 0.87) | 0.002 |
Radiation technique | ||||
IMRT | Reference | 1 | Reference | 1 |
2D/3D | 2.05 (1.64, 2.57) | < 0.001 | 1.57 (1.18, 2.09) | 0.002 |
RT delay | 1.46 (1.14, 1.88) | 0.003 | 1.08 (0.81, 1.45) | 0.586 |
Actual dose of radiation (cGy) | ||||
6600 | Reference | 1 | Reference | 1 |
< 6600 | 2.56 (1.56, 4.17) | < 0.001 | 1.89 (1.08, 3.33) | 0.026 |
Cisplatin schedule during CRT | ||||
Q1 week | Reference | 1 | ||
Q3 week | 1.36 (0.78, 2.38) | 0.284 | ||
Cisplatin dose during CRT | ||||
Intermediate | Reference | 1 | Reference | 1 |
Low | 1.46 (1.04, 2.06) | 0.028 | 0.86 (0.58, 1.27) | 0.444 |
High | 1.36 (1.07, 1.72) | 0.013 | 1.3 (0.99, 1.7) | 0.057 |
Chemotherapy interruption during CRT | 1.33 (1.07, 1.66) | 0.011 | 1.33 (0.99, 1.78) | 0.056 |
Chemotherapy delay during CRT | 1.52 (1.18, 1.96) | 0.001 | 0.93 (0.67, 1.3) | 0.685 |
Hospitalization during CRT | 2.39 (1.72, 3.32) | < 0.001 | 1.57 (1.08, 2.28) | 0.019 |
Chemotherapy termination during CRT | 1.17 (0.9, 1.52) | 0.244 | ||
Adjuvant chemotherapy | 0.63 (0.46, 0.85) | 0.002 | 0.59 (0.41, 0.84) | 0.003 |
All cisplatin-related complications | 1.44 (1.15, 1.79) | 0.001 | 1.16 (0.89, 1.51) | 0.274 |
AKD | 1.21 (0.93, 1.58) | 0.149 | ||
AKI | 1.91 (1.33, 2.74) | < 0.001 | ||